Navigation Links
Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
Date:1/8/2009

CARLSBAD, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that the Company will present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Stanley T. Crooke, M.D., Ph.D., Chairman and CEO of Isis, will provide an overview of the Company and an update on recent clinical and business activities.

The presentation will begin at 11:30 a.m. PT (2:30 p.m. ET) on Monday, January 12, 2009. To access the live audio webcast, log on to www.isispharm.com. In addition to the live webcast, the presentation will be archived for a limited time on the Company's Web site.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a joint owner of Regulus Therapeutics Inc., a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the finan
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...Newswire/ - Uploadable USB pedometers may be new, ... A combination of advanced accelerometer functiona...term concern over the accuracy of self-reported da...rd improved participation in a fitness program. ,...llness suppliers to integrate this technology. "Ou...
(Date:11/27/2009)...ance, Nov. 27 Team Garmin-Slipstre...edicated to ethical sporting and developing the ne...y that it will become Team Garmin-Transitions with...sor of the team. Transitions Optical is the world,...ng the most advanced photochromic technology in th...
(Date:11/27/2009)..., Nov. 27 Allrecipes.com , the ...iving traffic numbers, with more than 2.8 million ...clear picture of what was served on the biggest fo...eal in 2009 weighed in at 2,225 calories per servi...ccording to the Allrecipes site, Sweet Potato Pie...
(Date:11/26/2009)...wswire/ -- With cold and flu season upon us, it,s ...to control the spread of infections and avoid illn...ep ourselves healthy, but to avoid transmitting il... CIC (certified in infection-control), nursing dir...h at Hospital for Special Surgery (HSS) in Manhatt...
(Date:11/26/2009)... emotional rollercoaster, study finds , ,...e fear factor meets the jubilant sports fan. , ... those who root for the winning team -- enjoy the ...match and victory was in doubt, producing feelings... Thanksgiving weekend as you,re glued to the TV se...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...of Study Led by Mayo Clinic and USC Now Availabl...s to be published in the April 4, 2009 edition of ... the first to show definitively that computerized ... Southern California and the Mayo Clinic has been...
... Show surprises Dad of 16 year-old scho..., AZ. (PRWEB) February 11, 2009 -- It,s common kno...d and share many physical traits, but it,s a bit u...nched their first full webisode on their website ...
...O, Calif., Feb. 10 DaVita Inc.,(NYSE: DVA ) tod...d December,31, 2008. Net income for the three mont...0.94 per share, as compared to $85.7 million, or $...ed December 31, 2008 was $374.2 million, or,$3.53 ...
...eb. 10 More than 170 public health organizations ...rging them to maintain the House-passed level of f... American Reinvestment and Recovery Act of 2009. T...more than 20,000 public health jobs. As states, lo...
..., Calif., Feb. 10 Nationwide Health Properties, I...of Directors declared a $0.44 per share dividend o...rch 6, 2009 to shareholders of record on February ...ill be paid in cash on March 31, 2009 to sharehold...
...as HPV tweak their DNA to escape detection, study...News) -- The DNA of cancer-related viruses may act...e system, a new study has found. , An internationa...e pathogens can progress into cancer -- for exampl...
Other Medicine News:Health News:Published Study Shows Brain Exercises Improve Memory and Attention - And People Notice 2Health News:Published Study Shows Brain Exercises Improve Memory and Attention - And People Notice 3Health News:Bonus Footage From The Ground-breaking New Reality Show Hair Loss Confidential 2Health News:Bonus Footage From The Ground-breaking New Reality Show Hair Loss Confidential 3Health News:DaVita 4th Quarter 2008 Results 2Health News:DaVita 4th Quarter 2008 Results 3Health News:DaVita 4th Quarter 2008 Results 4Health News:DaVita 4th Quarter 2008 Results 5Health News:DaVita 4th Quarter 2008 Results 6Health News:DaVita 4th Quarter 2008 Results 7Health News:DaVita 4th Quarter 2008 Results 8Health News:DaVita 4th Quarter 2008 Results 9Health News:DaVita 4th Quarter 2008 Results 10Health News:DaVita 4th Quarter 2008 Results 11Health News:DaVita 4th Quarter 2008 Results 12Health News:DaVita 4th Quarter 2008 Results 13Health News:DaVita 4th Quarter 2008 Results 14Health News:DaVita 4th Quarter 2008 Results 15Health News:DaVita 4th Quarter 2008 Results 16Health News:DaVita 4th Quarter 2008 Results 17Health News:DaVita 4th Quarter 2008 Results 18Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 2Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 3Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 4Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 5Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 6Health News:Over 170 Groups Urge Bill Conferees to Include 'Double Duty' Public Health Funds in Stimulus for Jobs and Health Care Savings 7Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3Health News:Genes Help Cancer-Linked Viruses Elude Immune System 2
(Date:11/25/2009)...5 American Scientific Re...s pleased to announce that they have opened a regi... Shanghai, China. ,, ASR has been able to secur...y for the development and production of current an...nd adults to be distributed and sold globally. Cu...
(Date:11/25/2009)... Hologic, Inc. (Hologic ...per, manufacturer and supplier of premium diagnost... dedicated to serving the healthcare needs of wome... Society of North America (RSNA) at McCormick Plac... to highlight our new SecurView(®) DX multimo...
(Date:11/25/2009)... ERT (Nasdaq: ERES ), a...ompany,s President and CEO, and Keith Schneck, the...cheduled to present at the 21st Annual Piper Jaffr...er 1, 2009 in New York City, New York. ,, Inter...ing the Company,s corporate website at http://www...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2doeBilling Fully Compliant with International Billing Requirements 61356 1doeBilling Fully Compliant with International Billing Requirements 61356 2Nu Skin Declares Quarterly Dividend of 240 115 61354 1Journal of Hospice 26amp 3B Palliative Nursing Names New Editor 61352 1Journal of Hospice 26amp 3B Palliative Nursing Names New Editor 61352 2Journal of Hospice 26amp 3B Palliative Nursing Names New Editor 61352 3
...s to begin Phase IIb study in the first half of 20...cals, Inc., (Nasdaq: ALSE ), announced today that...inical trial of Cethrin in acute,spinal cord injur... at 9,sites in the United States and Canada. We ex...08 following protocol-specified patient,evaluation...
...nation Study of a MET and EGFR Inhibitor-, SOUTH ...aq: EXEL ) today announced that it has initiated ...all cell lung cancer (NSCLC) who have had,progress...b., XL184 is a small molecule that simultaneously... kinases. In the initial phase 1 part of the study...
Other Medicine Technology:Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 5Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4
...uronate (1.8%) viscoelastic solution combines maxi...ayflo maintains a deep anterior chamber and protec...is ideal for routine cataract surgery but can be u...oelastic. Combine all these properties with the co...
CoEase
..., non-pyrogenic, transparent viscoelastic preparat...lecular weight (average molecular weight 4 million... of sodium hyaluronate 5000, dissolved in repeatin...dium glucuronate linked by glycosidic bonds., ,...
ProVisc
Medicine Products: